Skin and soft tissue infections;Infecciones de piel y partes blandas

Medicina Clinica

Volumn 133, Issue 14, 2009, Pages 552-564

  Salgado Ordóñez, Fernando ^a   Arroyo Nieto, Ascensión ^b   Lozano Serrano, Ana Belén ^c   Hidalgo Conde, Ana ^d   Verdugo Carballeda, José ^e  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b Hospital General de Jaén   (Spain)

^c HOSPITAL DE PONIENTE   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BENZATHINE PENICILLIN; CEFALEXIN; CEFAZOLIN; CEFTRIAXONE; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DAPTOMYCIN; ERTAPENEM; ERYTHROMYCIN; FUSIDIC ACID; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METICILLIN; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PSEUDOMONIC ACID; QUINOLONE; TEICOPLANIN; UNINDEXED DRUG; VANCOMYCIN;

ABSCESS; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIOSTASIS; CELLULITIS; CHRONIC LIVER DISEASE; CLOSTRIDIUM; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; ECTHYMA; ERYSIPELAS; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; IMPETIGO; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIXED INFECTION; MYOSITIS; NAUSEA; NECROSIS; OPTIMAL DRUG DOSE; OXYGEN THERAPY; PATIENT MONITORING; PYOMYOSITIS; REPEATED DRUG DOSE; SHOCK; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PYOGENES; SURGICAL DRAINAGE; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ALGORITHMS; HUMANS; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS;

EID: 70349758452     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2008.11.021     Document Type: Article

References (116)

1. Pigrau C., and Barberán J. Infecciones de piel y partes blandas por grampositivos multirresistentes. Enferm Infecc Microbiol Clin 26 Sup 2 (2008) 21-30
2. Broseta A., Chaves F., Rojo P., and Otero J.R. Emergence of a single clone of community-associated methicillin-resistant Staphylococcus aureus in southern Madrid children. Enferm Infecc Microbiol Clin 24 (2006) 31-35
3. Sánchez U., and Peralta G. Infecciones de partes blandas: nomenclatura y clasificación. Enferm Infecc Microbiol Clin 21 (2003) 196-199
4. Kaiser R.E., and Cerra F.B. Progressive necrotizing surgical infections a unified approach. J Trauma 21 (1981) 349-355
5. Elliott D.C., Kufera J.A., and Myers R.A. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg 224 (1996) 672-683
6. Gross P.A., Barrett T.L., Dellinger P., Krause P.J., Martone W.J., McGowan Jr. J.E., et al. Purpose of quality standars for infectious diseases. Clin Infect Dis 18 (1994) 421
7. http://www.agreecollaboration.org/instrument/
8. http://www.saei.org
9. George A., and Rubin G. A systematic review and meta-analysis of treatments for impetigo. B J Gen Pract 53 (2003) 480-487
10. Eells L.D., Mertz P.M., Piovanetti Y., Pekoe G.M., and Eaglstein W.H. Topical antibiotic treatment of impetigo with mupirocin. Arch of Dermatol 122 (1986) 1273-1276
11. Ruby R.J., and Nelson J.D. The influence of hexachlorophene scrubs on the response to placebo or penicillin therapy in impetigo. Pediatrics 52 (1973) 854-859
12. Koning S., and Van der Wouden J.C. Treatment for impetigo. BMJ 329 (2004) 695-696
13. Yun H.J., Lee S.W., Yoon G.M., Kim S.Y., Choi S., Lee Y.S., et al. Prevalence and mechanisms of low and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother 51 (2003) 619-623
14. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J.C., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41 (2005) 1373-1406
15. Barton L.L., Friedman A.D., Sharkey A.M., Schneller D.J., and Swierkosz E.M. Impetigo contagiosa iii: Comparative efficacy of oral erythromycin and topical mupirocin. Pediatr penicillin, erythromycin, and cephalexin therapies. Pediatr Dermatol 6 (1989) 134-138
16. Briton J.W., Fajardo J.E., and Krafte-Jacobs B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr 117 (1990) 827-829
17. Owen S.E., and Cheesbrough J.S. Fusidic acid cream for impetigo. Findings cannot be extrapolated. BMJ 324 (2002) 1394
18. Stoddart B., Collyns T., and Denton M. Fusidic acid cream for impetigo. Problem may be clinically important. BMJ 324 (2002) 1394
19. Swartz M.N. Clinical practice: Cellulitis. N Eng J Med 350 (2004) 904-912
20. Perl B., Gottehrer N.P., Raveh D., Schlesinger Y., Rudensky B., and Yinnon A.M. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 29 (1999) 1483-1488
21. Sachs M.K. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 150 (1990) 1907-1912
22. Lebre C., Girard-Pipau F., Roujeau J.C., Revuz J., Saiag P., and Chosidow O. Value of fine-needle aspiration in infectious cellulitis. Arch Dermatol 132 (1996) 842-843
23. Semel J.D., and Goldin H. Association of athlete's foot with cellulitis of the lower extremities: Diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis 23 (1996) 1162-1164
24. Baddour LM. Epidemiology, clinical features and diagnosis of cellulitis. In: Rose BD, editor. UpToDate Online 14.3.
25. Schmid M.R., Kossmann T., and Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. Am J Roentgenol 170 (1998) 615-620
26. Jorup-Ronstrom C., Britton S., Gavlevik A., Gunnarsson K., and Redman A.C. The course, costs, and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 12 (1984) 390-394
27. Pérez-Trallero E., García de la Fuente C., García Rey C., Baquero F., Aguilar L., Dal-Ré R., et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 49 (2005) 1965-1972
28. Albrich W.C., Monnet D.L., and Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis 10 (2004) 514-517
29. Falagas M.E., Matthaiou D.K., and Vardakas K.Z. Fluoroquinolones vs beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: A meta-analysis of randomized controlled trials. Mayo Clinic Proc 81 (2006) 1553-1566
30. Hepburn M.J., Dooley D.P., Skidmore P.J., Ellis M.W., Starnes W.F., and Hasewinkle W.C. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 164 (2004) 1669-1674
31. Kragasakis K., Samonis G., Maniatakis P., Georgala S., and Tosca A. Bullous erisipelas: Clinical presentation, staphylococcal involvement and meticillin resistance. Dermatology 212 (2006) 31-35
32. Bergkvist P.I., and Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: A randomized, double blind, placebo-controlled study. Scand J Infect Dis 29 (1997) 377-382
33. Bergkvist P.I., and Sjobeck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: A 1-year follow-up. Scand J Infect Dis 30 (1998) 206-207
34. Morris A. Cellulitis and erysipelas. Clin Evid 15 (2006) 2207-2211
35. Karakas M., Baba M., Aksungur V.L., Denli Y.G., Memişoglu H.R., Aksungur E.H., et al. Manifestation of cellulitis after saphenous venectomy for coronary bypass surgery. J Eur Acad Dermatol Veneorol 16 (2002) 438-440
36. Crickx B., Chevron F., and Sigal-Nahum H. Erysipelas: Epidemiological, clinical and therapeutic data (111 cases). Ann Dermatol Venereol 118 (1991) 11-16
37. Kremer M., Zuckerman R., Avraham Z., and Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect 22 (1991) 37-40
38. Sjoblom A.C., Eriksson B., Jorup-Ronstrom C., Karkkonen K., and Lindqvist M. Antibiotic prophylaxis in recurrent erysipelas. Infection 21 (1993) 390-393
39. Wang J.H., Liu Y.C., Cheng D.L., Yen M.Y., Chen Y.S., Wang J.H., et al. Role of benzathine penicilin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis 25 (1997) 685-689
40. Stevens DL. Necrotizing infections of the skin and fascia. UpToDate Online 14.3.
41. Majeski J.A., and John J.F. Necrotizing soft tissue infections: A guide to early diagnosis and initial therapy. Review articles. South Med J 96 (2003) 900-905
42. Majeski J., and Majeski E. Necrotizing fasciitis: Improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J 90 (1997) 1065-1068
43. Stamenkovic I., and Lew P.D. Early recognition of potentially fatal necrotizing fasciitis: The use of frozen-section biopsy. N Eng J Med 310 (1984) 1689-1693
44. Guía terapéutica de las infecciones de piel y tejidos blandos. Rev Esp Quimiterap 19 (2007) 1-17
45. Green R.J., Dafoe D.C., and Raffin T. Necrotizing fasciitis review. Chest 110 (1996) 219-229
46. McHenry C.R., Piotrowski J.J., Petrinic D., and Malangoni M.A. Determinants of mortality for necrotizing soft-tissue infections. Annals of Surgery 221 (1995) 558-563
47. Voros D., Pissiotis C., Georgantas D., Katsaragakis S., Antoniou S., and Papadimitriou J. Role of early and extensive surgery in the treatment of severe necrotizing soft tissue infection. British Journal of Surgery 80 (1993) 1190-1191
48. Zibari G.B. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: A retrospective study. American Surgeon 64 (1998) 397-401
49. Ward R.G., and Walsh M.S. Necrotizing fasciitis 10 years experience in a district general hospital. British Journal of Surgery 78 (1991) 488-489
50. Baddour LM. Skin abscess. UpToDate Online 14.3.
51. Llera J.L., and Levy R.C. Treatment of cutaneous abscess: A double-blind clinical study. Ann Emerg Med 14 (1985) 15-19
52. Thirumalaikumar S., and Kommu S. Best evidence topics reports: Aspiration of breast abscesses. Emerg Med J 21 (2004) 333-334
53. Schwarz R.J., and Shrestha R. Needle aspiration of breast abscesses. Am J Surg 182 (2001) 117-119
54. Strauss A., Middendorf K., Muller-Egloff S., Heer I.M., Untch M., and Bauerfeind I. Sonographically guided percutaneous needle aspiration of breast abscesses-a minimal-invasive alternative to surgical incision. Ultras Med 24 (2003) 393-398
55. Abraham N., Doudle M., and Carson P. Open versus closed surgical treatment of abscesses: A controlled clinical trial. The Austr and New Z J Surg 67 (1997) 173-176
56. Stewart M.P., Laing M.R., and Krukowski Z.H. Treatment of acute abscesses by incision, curettage and primary suture without antibiotics: A controlled clinical trial. Br J Surg 72 (1985) 66-67
57. Simms M.H., Curran F., Johnson R.A., Oates J., Givel J.C., Chabloz R., et al. Treatment of acute abscesses in the casualty department. BMJ 284 (1982) 1827-1829
58. Edino S.T., Ihezue C.H., and Obekpa P.O. Outcome of primary closure of incised acute soft-tissue abscesses. Nig Postg Med J 1 (2001) 32-36
59. Wong C.H., Khin L.W., Heng K.S., Tan K.C., and Low C.O. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: A tool for distinguishing soft tissue infection from other soft tissue infections. Crit Care Med 32 (2004) 1535-1541
60. Wall D.B., De Virgilio C., Black S., and Klein S.R. Objective criteria may assist in distinguishing necrotizing fasciitis from non necrotizing soft tissue infection. Am J Surg 179 (2000) 17-21
61. Wang T.L., and Hung C.R. Role of tissue oxygen saturation monitoring in diagnosing necrotizing fasciitis of the lower limbs. Ann Emerg Med 44 (2004) 222-228
62. Eron L.J., Lipsky B.A., Low D.E., Nathwani D., Tice A.D., and Volturo G.A. Managing skin and soft tissue infections: Expert panel recommendations on key decision points. J Antimicrob Chemotherap 52 supp (2003) i3-i17
63. Lille S.T., Sato T.T., Engray L.H., Foy H., and Jurkovich G.J. Necrotizing soft tissue infections: Obstacles in diagnosis. J Am Coll Surg 182 (1996) 7-11
64. Struk D.W., Munk P.L., Lee M.J., Ho S.G., and Worsley D.F. Imaging of soft tissue infections. Radiologic Clinics of North America 39 (2001) 277-303
65. Ma L.D., Frassica F.J., Bluenke D.L., and Fishman E.K. CT and MRI evaluation of musculoskeletal infection. Crit Rev Diagn Imaging 38 (1997) 535-568
66. Willson D.J. Soft tissue and joint infection. Eur Radiol 14 (2004) 64-71
67. Robben S.G. Ultrasonography of musculoskeletal infections in children. Eur Radiol 14 (2004) 65-77
68. Akhtar M.S., Qaisar A., Irfanullah J., Iqbal J., Khan B., Jehangir M., et al. Antimicrobial peptide 99mTc-ubiquicidin 29-41 as human infection-imaging agent: Clinical trial. J Nucl Med 4 (2005) 567-573
69. Stumpe K.D. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 27 (2000) 822-832
70. Woo P.C., Lum P.N., Wong S.S., Cheng V.C., and Yuen K.Y. Cellulitis complicating lymphoedema. Eur J Clin Microbiol Infect Dis 19 (2000) 294-297
71. Lal A., Warren J., Bedrossian C.W.M., and Nayar R. The role of fine needle aspiration in diagnosis of infectious disease. Lab Med 33 (2002) 866-872
72. Sigurdson A.F., and Gudmunsson S. The etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis 21 (1989) 537-542
73. Bill T.J. Quantitative swab culture versus tissue biopsy: A comparison in chronic wounds. Osteomy Wound Manage 47 (2001) 34-37
74. Traylor K.K., and Todd J.K. Needle aspirate culture method in soft tissue infections: Injection of saline vs direct aspiration. The Pediatric Infectious Diseasse 17 (1998) 840-841
75. Park M.K., Myers R.A., and Marzella L. Oxygen tensions and infections: Modulation of microbial growth, activity of antimicrobial agents, and immunologic responses. Clin Infect Dis 14 (1992) 720-740
76. Desola J., Escola E., and Galofre M. Infecciones necrosantes de partes blandas. Perspectiva multidisciplinaria. Med Clin (Barc) 28 110 (1998) 431-436
77. Brown D.R., Davis N.L., Lepawsky M., Cunningham J., and Kortbeek J. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg 167 (1994) 485-489
78. Wilkinson D., and Doolette D. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg 139 (2004) 1339-1345
79. Hollabaugh Jr. R.S., Dmochowski R.R., Hickerson W.L., and Cox C.E. Fournier's gangrene: Therapeutic impact of hyperbaric oxygen. Plast Reconstr Surg 101 (1998) 94-100
80. Riseman J.A., Zamboni W.A., Curtis A., Graham D.R., Konrad H.R., and Ross D.S. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 108 (1990) 847-850
81. Korhonen K., Hirn M., and Niinikoski J. Hyperbaric oxygen in the treatment of Fournier's gangrene. Eur J Surg 164 (1998) 251-255
82. Shupak A., Shoshani O., Goldenberg I., Barzilai A., Moskuna R., and Bursztein S. Necrotizing fasciitis: An indication for hyperbaric oxygenation therapy?. Surgery 118 (1995) 873-878
83. Gabb G., and Robin E.D. Hyperbaric oxygen-a therapy in search of diseases. Chest 92 (1987) 1.074-82
84. Jallali N., Withey S., and Butler P.E. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg 189 (2005) 462-466
85. Desola J., Escolá E., Moreno E., Muñoz M.A., Sánchez U., and Murillo F. Tratamiento combinado de la gangrena gaseosa con oxigenoterapia hiperbárica, cirugía y antibióticos. Estudio colaborativo multicéntrico nacional. Med Clin (Barc) 94 (1990) 641-650
86. Sheridan R.L., and Shank E.S. Hyperbaric oxygen treatment: A brief overview of a controversial topic. J Trauma 2 (1999) 426-435
87. Norrby-Teglund A., Kaul R., Low D.E., McGeer A., Andersson J., Andersson U., et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 12 (1996) 5395-5398
88. Kaul R., McGeer A., Norrby-Teglund A., Kotb M., Schwartz B., O'Rourke K., et al., The Canadian Streptococcal Study Group. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: A comparative observational study. Clin Infect Dis 28 (1999) 800-807
89. Darenberg J., Ihendyane N., Sjölin J., Aufwerber E., Haidl S., Follin P., et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A european randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37 (2003) 333-340
90. Mehta S., McGeer A., Low D.E., Hallett D., Bowman D.J., Grossman S.L., et al. Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU. Chest 6 (2006) 1679-1686
91. Chapman S.J., Opdam H., Donato R., and Johnson P.D. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 8 (2006) 742-743
92. Lamothe F., D'Amico P., Ghosn P., Tremblay C., Braidy J., and Patenaude J.V. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: Case report and review. Clin Infect Dis 21 (1995) 1469-1470
93. Crum N.F., and Wallace M.R. Group B streptococcal necrotizing fasciitis and toxic shock-like syndrome: A case report and review of the literature. Scand J Infect Dis 35 (2003) 878-881
94. Haywood C.T., McGeer A., and Low D.E. Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast Reconstr Surg 103 (1999) 1567-1573
95. Alejandria M.M., Lansang M.A., Dans L.F., and Mantaring J.B.V. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2 (2001) CD001090. Updated 2002; Issue 1
96. Laupland K.B., Boucher P., Rotstein C., Cook D.J., and Doig C.J. Intravenous immunoglobulin for severe infections: A survey of Canadian specialists. J Crit Care 19 (2004) 75-81
97. Valiquette L., Low D.E., Chow R., and McGeer A.J. A survey of physician's attitudes regarding management of severe group A streptococcal infections. Scand J Infect Dis 38 (2006) 977-982
98. Moran D., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., and Carey R.B. Methicillin-resistant S. aureus infections among patients in the emergency department. N Eng J Med 355 (2006) 666-671
99. King M.D., Humphrey B.J., Wang Y.F., Kourbatova E.V., Ray S.M., and Blumberg H.M. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 144 (2006) 309-317
100. Cuevas O., Cercenado E., Bouza E., Castellares C., Trincado P., Cabrera R., et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Spain: A multicentre prevalence study (2002). Clin Microbiol Infect 13 (2007) 250-256
101. Rodríguez-Baño J, Cisneros JM, Moreno I, Salas J, Pascual A. Documento de consenso sobre el manejo de las Infecciones causadas por S. aureus resistente a meticilina en adultos. http://saei.org.
102. Lang E., Foldes M., and Marghescu S. Teicoplanin in the treatment of skin and soft tissue infections: Results of a multicentre study. Infection 19 (1991) 190-194
103. Brooks A.D., and Zervos M.D. New antimicrobial agents for gram-positive infections. Curr Op Inrfect Dis 11 (1998) 667-671
104. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., Knirsch C., et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
105. Itani K.M., Weigelt J., Li J.Z., and Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 26 (2005) 442-448
106. Sharpe J.N., Shively E.H., and Polk H.C. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 189 (2005) 425-428
107. Plosker G.L., and Figgitt D.P. Linezolid: A pharmacoeconomic review of its use in serious gram-positive infections. Pharmacoeconomics 23 (2005) 945-964
108. Moellering R.C. Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med 21 138 (2003) 135-142
109. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., and Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 Suppl. 5 (2005) S341-S353
110. Postier G., Green S.L., Klein S.R., Ellis-Grosse E.J., and Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 26 (2004) 704-714
111. Garau J. Management of cSSTIs: The role of daptomycin. Curr Med Res Opin 22 (2006) 2079-2087
112. Kern W.V. Daptomycin: First in a new class of antibiotics for complicated skin and soft-tissue infections. Int J Clin Pract 60 (2006) 370-378
113. Ryback R.J. The efficacy and safety of daptomycin: First in a new class of antibiotics for gram-positive bacteria. Clin Microbiol Infect 12 Suppl 1 (2006) 24-32
114. Arbeit R.D., Maki D., Tally F.P., Campanaro E., and Eisenstein B.I. Clin Infect Dis 38 (2004) 1673-1681
115. Szumowski J.D., Cohen D.E., Kanaya F., and Mayer K.H. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 5 (2007) 423-428
116. Markowitz N., Quinn E.L., and Saravolatz L.D. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 117 (1992) 390-398